Common use of Closings; Use of Proceeds Clause in Contracts

Closings; Use of Proceeds. The sale and purchase of the Convertible Notes and Warrants to be purchased by the Investors shall take place at one or more closings (each a “Closing” and collectively with the Additional Closings (as defined below), the “Closings”) to be held at such places and times as the Company and the applicable Investors may determine (each a “Closing Date” and collectively “Closing Dates”). At each Closing, the Company will deliver to each of the applicable Investors the Convertible Note and the Warrant to be purchased by such Investor dated the date of the Closing and registered in such Investor’s name, against receipt by the Company of such Investor’s Investment Amount for the account of the Company by wire transfer of immediately available funds in accordance with the Company’s instructions. The Company may conduct additional Closings at the Company’s option in the Company’s sole discretion (each, an “Additional Closing”) to be held at such places and times as the Company and the Investors participating in such Additional Closing may determine (each, an “Additional Closing Date”). The proceeds of the Convertible Notes and Warrants shall be used for costs and expenses of the Company in connection with research and development, general and administrative purposes and working capital.

Appears in 1 contract

Samples: Convertible Note and Warrant Purchase Agreement (RespireRx Pharmaceuticals Inc.)

AutoNDA by SimpleDocs

Closings; Use of Proceeds. The sale and purchase of the Convertible Notes Common Stock and Warrants to be purchased by the Investors shall take place at one or more closings (each a “Closing” and collectively with the Additional Closings (as defined below)collectively, the “Closings”) to be held at such places and times as the Company and the applicable Investors may determine (each a “Closing Date” and collectively “Closing Dates”). At each Closing, the Company will deliver to each of the applicable Investors the Convertible Note Common Stock and the Warrant Warrants to be purchased by such Investor dated the date of the Closing and registered in such Investor’s name, against receipt by the Company of such Investor’s Investment Amount from the escrow agent for the offering, for the account of the Company by wire transfer of immediately available funds in accordance with the Company’s and the placement agent’s (“Placement Agent”) instructions. The Company may conduct additional Closings at the Company’s option in the Company’s and Placement Agent’s sole discretion (each, an “Additional Closing”) to be held at such places and times Closing Dates as the Company Company, the Placement Agent and the Investors participating in such Additional Closing Closings may determine (each, an “Additional Closing Date”)determine. The proceeds from the sale of the Convertible Notes Common Stock and Warrants shall be used for costs and expenses of the Company in connection with research and development, general and administrative purposes purposes, and working capital. The final Closing shall be no later than September 29, 2017 unless extended until December 30, 2017.

Appears in 1 contract

Samples: Common Stock and Warrant Purchase Agreement (RespireRx Pharmaceuticals Inc.)

Closings; Use of Proceeds. The sale and purchase of the Convertible Notes Common Stock and Warrants to be purchased by the Investors shall take place at one or more closings (each a “Closing” and collectively with the Additional Closings (as defined below)collectively, the “Closings”) to be held at such places and times as the Company and the applicable Investors may determine (each a “Closing Date” and collectively “Closing Dates”). At each Closing, the Company will deliver to each of the applicable Investors the Convertible Note Common Stock and the Warrant Warrants to be purchased by such Investor dated the date of the Closing and registered in such Investor’s name, against receipt by the Company of such Investor’s Investment Amount from the escrow agent for the offering, for the account of the Company by wire transfer of immediately available funds in accordance with the Company’s and the placement agent’s (“Placement Agent”) instructions. The Company may conduct additional Closings at the Company’s option in the Company’s and Placement Agent’s sole discretion (each, an “Additional Closing”) to be held at such places and times Closing Dates as the Company Company, the Placement Agent and the Investors participating in such Additional Closing Closings may determine (each, an “Additional Closing Date”)determine. The proceeds from the sale of the Convertible Notes Common Stock and Warrants shall be used for costs and expenses of the Company in connection with research and development, general and administrative purposes purposes, and working capital. The final Closing shall be no later than October 31, 2016 unless extended until December 31, 2016.

Appears in 1 contract

Samples: Common Stock and Warrant Purchase Agreement (RespireRx Pharmaceuticals Inc.)

AutoNDA by SimpleDocs

Closings; Use of Proceeds. The sale and purchase of the Convertible Notes Common Stock and Warrants to be purchased by the Investors shall take place at one or more closings (each a “Closing” and collectively with the Additional Closings (as defined below)collectively, the “Closings”) to be held at such places and times as the Company and the applicable Investors may determine (each a “Closing Date” and collectively “Closing Dates”). At each Closing, the Company will deliver to each of the applicable Investors the Convertible Note Common Stock and the Warrant Warrants to be purchased by such Investor dated the date of the Closing and registered in such Investor’s name, against receipt by the Company of such Investor’s Investment Amount from the escrow agent for the offering, for the account of the Company by wire transfer of immediately available funds in accordance with the Company’s and the placement agent’s (“Placement Agent”) instructions. The Company may conduct additional Closings at the Company’s option in the Company’s and Placement Agent’s sole discretion (each, an “Additional Closing”) to be held at such places and times Closing Dates as the Company Company, the Placement Agent and the Investors participating in such Additional Closing Closings may determine (each, an “Additional Closing Date”)determine. The proceeds from the sale of the Convertible Notes Common Stock and Warrants shall be used for costs and expenses of the Company in connection with research and development, general and administrative purposes purposes, and working capital. The final Closing shall be no later than March 31, 2017 unless extended until June 30, 2017.

Appears in 1 contract

Samples: Common Stock and Warrant Purchase Agreement (RespireRx Pharmaceuticals Inc.)

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!